Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2016

argenx announces publication of seminal data supporting the therapeutic potential of ARGX-110 for acute myeloid leukemia in the Journal of Experimental Medicine

December 29, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the publication of new preclinical data on the CD70/CD27 pathway that provide further rationale for ARGX-110 therapy for the treatment of acute myeloid leukemia (AML). ARGX-110, a SIMPLE Antibody™ targeting CD70, is currently being evaluated in a Phase I/II study in combination with azacitidine in newly diagnosed AML patients.

argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

December 15, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the initiation of a Phase I/II clinical trial of ARGX-110 in combination with azacitidine in newly diagnosed, elderly acute myeloid leukemia (AML) patients. ARGX-110 is the Company’s SIMPLE Antibody™ targeting CD70. Azacitidine is a hypomethylating agent that upregulates CD70 expression on AML blasts, and is currently the standard of care treatment for elderly AML patients. 

argenx to provide updates on ARGX-113 and ARGX-110 during American Society of Hematology Annual Meeting

December 02, 2016

Workshop to occur on Sunday December 4th at 11:00 am PT 

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will provide updates on its two lead programs, ARGX-113 and ARGX-110, during a workshop being held today in conjunction with the American Society of Hematology (ASH) Annual Meeting. 

argenx to Present at Upcoming Investor Conferences

November 08, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that management will present at several upcoming investor conferences in November:

argenx Reports Third Quarter 2016 Financial Results and Provides Business Update

October 27, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided a business update and announced financial results for the third quarter ended 30 September 2016.

Frost & Sullivan Applauds argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPLE Antibody™

October 05, 2016

argenx’s specific drug candidates include ARGX-113 for myasthenia gravis, ARGX-110 for cancer immunotherapy, and ARGX-111 for c-MET

London UK / Breda, the Netherlands / Ghent, Belgium Based on its recent analysis of the therapeutic antibody engineering market, Frost & Sullivan recognises argenx N.V. with the 2016 European Frost & Sullivan Award for Technology Innovation. argenx’s SIMPLE Antibody™ discovery platform is a huge improvement on conventional antibody discovery platforms because it yields an unprecedented epitope coverage, allowing to interact with the disease biology in a much more precise manner. The application diversity of the platform enables it to generate a wide array of antibodies for different types of cancer and autoimmune disorders.

argenx provides update on lead programs in auto-immune disease and oncology at R&D day in New York

September 22, 2016

  • Myasthenia gravis and immune thrombocytopenia named as initial indications for Phase 2 studies of ARGX-113
  • T-cell lymphoma and acute myeloid leukemia named as indications for Phase 2 combination studies for ARGX-110  

 

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provided highlights from its lead pipeline programs, ARGX-113 and ARGX-110, during its R&D in New York City.

argenx to host inaugural R&D day and webcast on September 22, 2016

September 15, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host its inaugural R&D day on Thursday, September 22, 2016 from 9:00 a.m. -12:00 p.m. ET in New York City.  

argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results

August 26, 2016

  • Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113
     in healthy volunteers
  • Phase 2 study in first auto-immune indication planned to start by year-end
  • Cash position strengthened by $40M upfront payment from AbbVie and
    €30M private placement

Management to host conference call today at 3 pm CET / 9 am EDT

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its second quarter business update and half year financial results for 2016, in accordance with IFRS as adopted by the European Union. 

argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016

August 19, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, August 26, 2016 at 3:00pm CET (9:00am EDT) to discuss financial results for the first half of 2016, as well as to provide a second quarter business update.

argenx to Present at Wedbush PacGrow Healthcare Conference

August 10, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present a corporate update at the Wedbush PacGrow Healthcare Conference in New York City (NY, USA) on Wednesday, August 17, 2016 at 8:35 am ET.

The presentation will be webcast live and may be accessed on the argenx website at www.argenx.com or by clicking here. A replay of the webcast will be available for 90 days following the presentation. 

argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers

June 30, 2016

  • Data show potent reduction of IgG levels of up to 85% and a favorable safety and tolerability profile
  • Phase 2 trial in myasthenia gravis expected to begin by end of 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced initial results from its Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers.  The compound continues to show favorable safety and tolerability across multiple doses and dosing regimens with promising pharmacodynamics effects relating to speed, depth and duration of IgG reduction. 

argenx announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016

June 10, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the presentation of efficacy and safety data from its Phase 1 expansion study of ARGX-110 in patients with T-cell lymphoma (TCL) during an e-poster session at the European Hematology Association (EHA) Annual Congress (Copenhagen, Denmark). 

argenx successfully closes €30 million private placement

June 03, 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111

June 03, 2016

  • Additional preclinical data support potential of ARGX-111 in targeting tumor microenvironment

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today announced data published in conjunction with the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting (Chicago, USA) presenting efficacy and safety data from its ARGX-111 Phase 1 expansion study in patients with MET amplified tumors. The data confirm ARGX-111 to have a favorable safety profile and to continue to show signs of anti-tumor activity. The abstract can be accessed here

 

argenx announces private placement of 2,703,000 new shares for an aggregate amount of €30 million with institutional investors

June 01, 2016

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

argenx reports first quarter 2016 financial results and provides business update

May 11, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced financial results for the first quarter ended 31 March 2016. 

argenx announces results of Annual General Meeting 2016

April 28, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET. 

argenx and AbbVie to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

April 21, 2016

  • argenx Management to Discuss Collaboration on Conference Call Today at 6 pm CET / noon EDT

BREDA, THE NETHERLANDS/GHENT, BELGIUM and NORTH CHICAGO, Ill., AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115. ARGX-115 is argenx' preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immunosuppressive effects of T-cells. 

argenx announces Annual General Meeting of Shareholders 28 April 2016

March 16, 2016

Breda, the Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX, hereinafter: the "Company"), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces that an annual general meeting of shareholders will be held on Thursday 28 April 2016.

argenx’s Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 to Treat Rheumatoid Arthritis

March 16, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today reported that its partner Bird Rock Bio (formerly RuiYi), a company focused on the discovery and development of novel biologic therapies, has announced  that gerilimzumab, a novel SIMPLE AntibodyTM neutralizing the IL-6 cytokine,  has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing. 

argenx reports fourth quarter business update and full year 2015 financial results

March 11, 2016

  • Clinical programs in severe auto-immune diseases and oncology
  • Supported by strong financial position
  • Management to host conference call today at 3 pm CET / 9 am EDT

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its fourth quarter business update and full year results for 2015, in accordance with IFRS as adopted by the European Union.

The full year results will be discussed during a conference call and webcast presentation today at 3 pm CET / 9 am EDT. To participate in the conference call, please select your phone number below, and use the confirmation code 61559035. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2015 Financial Results on 11 March 2016

March 03, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, 11 March 2016 at 3:00 pm CET (9:00 am ET) to discuss the 2015 financial results, as well as provide a fourth quarter business update.  

argenx: Home Member State Selection

February 26, 2016

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that following the implementation of the amended EU Transparency Directive (2013/50/EU), arGEN-X NV is required to publicly announce its Home Member State. In accordance with this regulation, the company announces that its Home Member State is the Netherlands.

argenx opens clinical trial sites in South Korea for ARGX-111 program

February 18, 2016

Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, today announced the opening of three clinical trial sites in South Korea for the recruitment of MET-amplified cancer patients for the Phase 1 safety expansion cohort of ARGX-111. 

argenx to present at the LEERINK Partners 5th Annual Global Healthcare Conference

February 05, 2016

Breda, the Netherlands / Ghent, Belgium– argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at the Leerink Partners 5th Annual Global Healthcare Conference in New York City (NY, USA) on Thursday, February 11, 2016 at 1:50pm ET.

argenx receives milestone payment in LEO Pharma collaboration

February 02, 2016

Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has received a milestone payment in connection with its collaboration with LEO Pharma. The companies have selected a lead cell line for manufacture of the licensed SIMPLE AntibodyTM candidate, in development for the treatment of inflammatory skin conditions.

argenx successfully closes transaction with US funds advised by subsidiaries of Federated Investors

January 22, 2016

argenx announces € 16 M investment by US funds advised by subsidiaries of Federated Investors

January 19, 2016

argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

January 06, 2016

  • Favourable safety and tolerability profile observed
  • Rapid reduction of IgG levels

Breda, the Netherlands / Ghent, Belgiumargenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it has completed the dose-escalation part of a Phase 1 study of ARGX-113. Initial results show the compound to be safe and well-tolerated across all doses in healthy volunteers.